Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in RAI-Refractory DTC
NCT02041260Phase 2Unknown
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2014
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in differentiated thyroid cancer (DTC), sponsored by Thomas Jefferson University. Primary endpoints: Number of Adverse Events at 3 years and Objective Response Rate. Status: unknown.
02
Drugs
cabozantinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02041260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041260.